Takeda Pharmaceutical Company Limited
TKPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.32 | -0.06 | 0.03 | -0.94 |
| FCF Yield | 4.76% | 2.20% | 1.74% | 4.91% |
| EV / EBITDA | 34.12 | 23.99 | 157.74 | 44.94 |
| Quality | ||||
| ROIC | -0.23% | 1.25% | -0.59% | 0.46% |
| Gross Margin | 65.85% | 65.24% | 63.73% | 63.56% |
| Cash Conversion Ratio | -32.25 | 1.73 | -2.15 | 16.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.06% | 2.89% | 4.39% | 5.10% |
| Free Cash Flow Growth | 131.84% | 8.44% | -60.43% | 73.52% |
| Safety | ||||
| Net Debt / EBITDA | 12.53 | 9.46 | 56.31 | 17.74 |
| Interest Coverage | 0.83 | 1.72 | -3.34 | 2.12 |
| Efficiency | ||||
| Inventory Turnover | 0.29 | 0.31 | 0.31 | 0.33 |
| Cash Conversion Cycle | 260.57 | 246.96 | 276.06 | 227.57 |